Cover Image
Market Research Report

Bronchopulmonary Dysplasia - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 213096
Published Content info 68 Pages
Delivery time: 1-2 business days
Price
Back to Top
Bronchopulmonary Dysplasia - Pipeline Review, H1 2019
Published: April 29, 2019 Content info: 68 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H1 2019, provides an overview of the Bronchopulmonary Dysplasia (Respiratory) pipeline landscape.

Bronchopulmonary dysplasia (BPD) is a form of chronic lung disease that develops in preterm neonates treated with oxygen and positive-pressure ventilation. Symptoms of BPD include tachypnea, tachycardia, increased respiratory effort (with retractions, nasal flaring, and grunting) and bluish skin color. Risk factors include congenital heart disease and severe respiratory or lung infection, premature babies who have a low birth weight seem to be at greater risk for developing BPD. Treatment includes bronchodilators, diuretics and antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bronchopulmonary Dysplasia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchopulmonary Dysplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Bronchopulmonary Dysplasia (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchopulmonary Dysplasia (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchopulmonary Dysplasia (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchopulmonary Dysplasia (Respiratory)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchopulmonary Dysplasia (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11161IDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bronchopulmonary Dysplasia - Overview
    • Bronchopulmonary Dysplasia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bronchopulmonary Dysplasia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bronchopulmonary Dysplasia - Companies Involved in Therapeutics Development
    • Chiesi Farmaceutici SpA
    • Ethypharm SA
    • Insmed Inc
    • MediPost Co Ltd
    • Meridigen Biotech Co Ltd
    • Radikal Therapeutics Inc
    • Syntrix Biosystems Inc
    • Takeda Pharmaceutical Co Ltd
    • The Cell-Factory BVBA
    • Therabron Therapeutics Inc
    • United Therapeutics Corp
  • Bronchopulmonary Dysplasia - Drug Profiles
    • AT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • caffeine citrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CFMEV-132 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mecasermin rinfabate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit FLT1 for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pioglitazone + B-YL - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pneumostem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-908 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein to Replace Surfactant Protein D for Bronchopulmonary Dysplasia and Lung Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bronchopulmonary Dysplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SX-576 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMC-11901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UNEX-42 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitamin A palmitate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bronchopulmonary Dysplasia - Dormant Projects
  • Bronchopulmonary Dysplasia - Discontinued Products
  • Bronchopulmonary Dysplasia - Product Development Milestones
    • Featured News & Press Releases
      • Feb 27, 2019: Esperite N.V. with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of bronchopulmonary dysplasia.
      • Nov 06, 2018: Esperite Group with The Cell Factory expands its extracellular vesicles product portfolio of anti-inflammatory drugs with a fourth indication : Bronchopulmonary Dysplasia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Bronchopulmonary Dysplasia, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by Chiesi Farmaceutici SpA, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by Ethypharm SA, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by Insmed Inc, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by MediPost Co Ltd, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by Meridigen Biotech Co Ltd, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by Radikal Therapeutics Inc, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by Syntrix Biosystems Inc, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by The Cell-Factory BVBA, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by Therabron Therapeutics Inc, H1 2019
  • Bronchopulmonary Dysplasia - Pipeline by United Therapeutics Corp, H1 2019
  • Bronchopulmonary Dysplasia - Dormant Projects, H1 2019
  • Bronchopulmonary Dysplasia - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Bronchopulmonary Dysplasia, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Top 10 Molecule Types, H1 2019
Back to Top